Ginkgo Bioworks Files Routine 8-K, Updates Corporate Info
Ticker: DNABW · Form: 8-K · Filed: Jan 10, 2024 · CIK: 1830214
| Field | Detail |
|---|---|
| Company | Ginkgo Bioworks Holdings, Inc. (DNABW) |
| Form Type | 8-K |
| Filed Date | Jan 10, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $11.50 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: corporate-update, compliance, administrative
TL;DR
**Ginkgo Bioworks filed a routine 8-K, no new financial news, just corporate info updates.**
AI Summary
Ginkgo Bioworks Holdings, Inc. filed an 8-K on January 10, 2024, primarily to update its corporate information and confirm its status as a public company. This filing, while not containing new financial results, serves as a routine administrative update, confirming the company's address in Boston, MA, and its Delaware incorporation. For investors, this filing is a standard procedural update and doesn't introduce new material information that would significantly alter investment decisions, but it reaffirms the company's ongoing compliance with SEC regulations.
Why It Matters
This filing is a standard administrative update, confirming Ginkgo Bioworks' corporate details and ongoing SEC compliance, which is important for maintaining transparency and investor confidence.
Risk Assessment
Risk Level: low — This 8-K is a procedural filing with no new material financial or operational information, posing minimal risk.
Analyst Insight
A smart investor would note this as a routine compliance filing and not expect any immediate market impact. It's a good reminder to check for more substantive filings like 10-Qs or 10-Ks for actual financial performance updates.
Key Players & Entities
- Ginkgo Bioworks Holdings, Inc. (company) — the registrant filing the 8-K
- January 10, 2024 (date) — date of earliest event reported and filing date
- Boston, MA (location) — address of principal executive offices
- Delaware (location) — state of incorporation
- 001-40097 (other) — Commission File Number
- 87-2652913 (other) — IRS Employer Identification No.
FAQ
What was the primary purpose of Ginkgo Bioworks Holdings, Inc.'s 8-K filing on January 10, 2024?
The primary purpose of the 8-K filing on January 10, 2024, was to report a current event, specifically updating corporate information and confirming the company's details, as indicated by the 'Date of Report (Date of earliest event reported): January 10, 2024'.
What is the current address of Ginkgo Bioworks Holdings, Inc. as stated in the filing?
According to the filing, the current address of Ginkgo Bioworks Holdings, Inc. is '27 Drydock Avenue 8th Floor Boston, MA 02210'.
In which state is Ginkgo Bioworks Holdings, Inc. incorporated?
Ginkgo Bioworks Holdings, Inc. is incorporated in 'Delaware', as stated under 'State or other jurisdiction of incorporation'.
What is the Commission File Number for Ginkgo Bioworks Holdings, Inc.?
The Commission File Number for Ginkgo Bioworks Holdings, Inc. is '001-40097', as listed in the filing.
Does this 8-K filing contain any new financial results or operational updates?
No, this 8-K filing does not contain any new financial results or significant operational updates. The 'ITEM INFORMATION' sections only list 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits' without providing new data, indicating a routine administrative filing rather than a substantive disclosure of new financial performance.
Filing Stats: 547 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-01-10 07:37:53
Key Financial Figures
- $0.0001 — stered Class A common stock, par value $0.0001 per share DNA NYSE Warrants to purchas
- $11.50 — mon stock, each at an exercise price of $11.50 per share DNA.WS NYSE Indicate by che
Filing Documents
- dna-20240110.htm (8-K) — 27KB
- ex-991jpm11024.htm (EX-99.1) — 21KB
- logoa.jpg (GRAPHIC) — 3KB
- 0001628280-24-001000.txt ( ) — 225KB
- dna-20240110.xsd (EX-101.SCH) — 2KB
- dna-20240110_def.xml (EX-101.DEF) — 16KB
- dna-20240110_lab.xml (EX-101.LAB) — 31KB
- dna-20240110_pre.xml (EX-101.PRE) — 16KB
- dna-20240110_htm.xml (XML) — 4KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On January 10, 2024, Ginkgo Bioworks Holdings, Inc. issued a press release announcing certain preliminary unaudited revenue highlights and performance updates for the year ended December 31, 2023. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1. The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release, issued by Ginkgo Bioworks Holdings, Inc. on January 10, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GINKGO BIOWORKS HOLDINGS, INC. Date: January 10, 2024 By: /s/ Mark Dmytruk Name: Mark Dmytruk Title: Chief Financial Officer